IntroductIon
Vancomycin, a glycopeptide bactericidal antibiotic, is used primarily to treat resistant Gram positive pathogens. In recent years, vancomycin use has increased dramatically secondary to increased incidence of methicillin resistant Staphylococcus aureus (MRSA) infections. 1, 2 Ototoxicity (especially with other ototoxic drugs) and nephrotoxicity are well known side-effects of vancomycin 3 ; vancomycin-induced severe thrombocytopenia has rarely been reported in the literature and can cause asymptomatic laboratory abnormalities to life-threatening bleeding. Here we present a rare case of severe vancomycin-induced immune mediated thrombocytopenia without symptoms that resolved after discontinuation of vancomycin.
cAse PresenttIon
A 63-year-old man with a history of uncontrolled diabetes mellitus presented with low grade fever and a diabetic right foot ulcer for three weeks. The rest of review of systems was unremarkable. His examination revealed temperature 101°F, heart rate 88 beats/minute, respiratory rate 18 breaths/minute, and blood pressure 130/70 mmHg. Examination of the foot revealed a small, purulent ulcer with surrounding cellulitis on the planter surface of the right big toe extending to the second and third toes with normal pulses in the foot. The remainder of the physical examination was unremarkable. Magnetic resonance imaging of the right foot confirmed a small abscess in the first right toe area. He underwent debridement and drainage of the abscess, where infected tissue was found extending to the first metatarsal bone and phalanx of the toe. The patient was started on empiric vancomycin and piperacillin-tazobactam intravenously (IV). Bone tissue cultures were positive for methicillin sensitive Staphylococcus aureus (MSSA) and MRSA.
Blood cultures at admission were positive for MSSA. Transthoracic and transesophageal echocardiograms were negative for vegetations. Repeat blood cultures on hospital day three were negative, and antibiotics were switched to IV vancomycin. The patient was discharged on hospital day seven on IV vancomycin for six weeks with wound care as an outpatient. He was advised to have a complete blood count, C-reactive protein, basic metabolic panel, and vancomycin trough levels every week.
One week later, the laboratory reported the platelet count was 2,000/mm 3 (manually confirmed); it was 206,000/mm 3 one week prior. The white blood cell count (WBC) was 1,200/mm 3 with 60% lymphocytes, 4% eosinophils, and 8% neutrophils; one week prior the WBC was 7,800/mm 3 . He was immediately readmitted into the hospital. He denied bleeding, hemoptysis, melena, hematochezia, fever, skin rash, or worsening of his lower extremity pain. Other tests included hemoglobin 9.4 g/dl, peripheral smears with normal platelet morphology with no clumping, prothrombin time 11.3 second (normal 11.2-14s), activated prothrombin time 28.5 second (normal 21.4-33.1s), total bilirubin 1.2mg/dl, serum creatinine 1.2mg/dl, and vancomycin level of 16.3 µg/mL. The heparin associated antibody was 1.159 OD (normal <0.399), but the serotonin release assay test was negative.
Vancomycin was immediately stopped, and IV daptomycin and empiric meropenem were added. His acute viral hepatitis panel, serum haptoglobin, serum lactate dehydrogenase level, anti-nuclear antibody (IgG), serum B12 level, parvovirus B19 IgM, parvovirus B19 by PCR, Epstein-Barr antibody viral-capsid antigen IgM, and flow cytometry results were all negative. The patient received single donor platelets transfusions for three consecutive days as preemptive therapy. Filgrastim (human granulocyte colonystimulating factor) injection was given for four days, and his neutropenia resolved in 72 hours. Vancomycin-induced immune platelet IgG antibody was positive. The patient's platelet count improved to 80,000/ mm 3 on day six and returned to baseline 213,000/ mm 3 on day 10 after discontinuation of vancomycin. Neutropenia was probably related to partial bone marrow suppression due to vancomycin, and the WBC count normalized to 6,500/mm 3 after discontinuation of vancomycin. The patient completed four weeks of daptomycin therapy as an outpatient with no relapse of thrombocytopenia or leukopenia.
dIscussIon
Drug-induced immune thrombocytopenia is a challenging clinical problem that is often overlooked. 4 The incidence of drug-induced thrombocytopenia is not well defined in the medical literature. Based on several reports from the United States and Europe, the estimated incidence is around 10 cases per million population per year, but the number could be higher in hospitalized or elderly patients. 5 Drug-induced thrombocytopenia typically results from either non-immune or immune mediated mechanisms. Non-immune thrombocytopenia is common and results from the suppression of platelet production by general myelotoxicity (e.g., chemotherapy agents), dose-dependent myelosuppression (e.g., linezolid), or interference with specific megakaryocyte function (e.g., bortezomib). Immune-mediated thrombocytopenia results from platelet destruction by drug-dependent platelet antibodies in the circulation. Several mechanisms have been proposed for immune-mediated thrombocytopenia, including: a) classic drug-dependent platelet antibodies (e.g., quinine); b) hapten-induced antibodies (e.g., penicillin); c) fiban-dependent antibodies (e.g., tirofiban); d) Fabbinding monoclonal antibodies (e.g., abciximab); e) drug-induced autoantibody formation (e.g., gold); f) immune complex formation (e.g., heparin). 6 Vancomycin-induced thrombocytopenia is postulated to be mediated by vancomycin-dependent immunoglobulin antibodies that bind specifically to platelet glycoprotein IIb and/ or IIIa and lead to platelet destruction. The antibodies formed in the presence of vancomycin appear to act like antibodies induced by quinine. 7, 8 Drygalski et al reported a large case series of vancomycin-induced immune thrombocytopenia. Vancomycin dependent, platelet-reactive
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Yasir Ahmed Vancomycin-induced Immune Thrombocytopenia patient received preemptive single donor platelets transfusion therapy for three consecutive days before the vancomycin IgG antibody test came back positive; the platelet count returned to baseline on day 10 after stopping vancomycin. He went home on IV daptomycin to complete the remaining course for right foot osteomyelitis treatment. Vancomycin rechallenge was not done due to very severe thrombocytopenia with initial therapy and confirmation of diagnosis by presence of vancomycin-induced immune platelet antibody.
In conclusion, vancomycin-induced severe immune thrombocytopenia has rarely been reported as a cause of thrombocytopenia. Physicians should monitor complete blood count and renal function closely in patients on vancomycin. Testing for vancomycin-induced immune platelet antibodies can be helpful in early diagnosis. Prompt resolution of thrombocytopenia occurs if the diagnosis is made in a timely manner, and vancomycin is discontinued.
antibodies in the immunoglobulin G class, immunoglobulin M class, or both were identified in 34 patients (20%). The mean nadir platelet count was 13,600/ mm 3 , and severe bleeding occurred in 10 (34%) cases. Platelet counts returned to baseline in all surviving patients after discontinuing vancomycin. 7 Early diagnosis of vancomycin-induced immune thrombocytopenia is essential to avoid life threatening bleeding. The diagnosis requires exclusion of common causes of thrombocytopenia, especially disseminated intravascular coagulation (DIC), a variety of infectious diseases that potentially cause thrombocytopenia, drugs, immunologic disorders, and hematologic malignancies, and a temporal relationship of the drug. The presence of vancomycininduced immune platelet antibody and resolution of thrombocytopenia after discontinuing the vancomycin confirms the diagnosis in most cases. 9 The main treatment is to stop vancomycin and avoid future use. In most cases, platelet count will recover promptly. The role of IV immunoglobulin (IgG) is unclear but can be used in patients with severe bleeding. 10 Our patient had asymptomatic vancomycininduced severe immune thrombocytopenia; his platelet count dropped to 2,000/mm 3 from his baseline 204,000/ mm 3 on the 15th day of vancomycin administration. Vancomycin was changed to daptomycin. After excluding other common causes, the diagnosis was confirmed by the presence of vancomycininduced immune platelet IgG antibodies (tests were performed at a reference laboratory, Blood Center of the Wisconsin Platelet and Neutrophil Immunology laboratory, Milwaukee, WI) by using immunofluorescence flow cytometry and resolution of thrombocytopenia after discontinuation of vancomycin. Our patient had very severe thrombocytopenia, and this degree of thrombocytopenia without symptoms has been rarely documented in the literature. Mizon et al reported a case with vancomycin-induced severe thrombocytopenia with a platelet count of 2,000/mm
